ACCRU leadership is now collaborating with Quorum Review IRB to provide a central institutional review board option for network members participating in oncology trials.
(SEATTLE, WA): Quorum Review IRB today announced collaboration with Academic and Community Cancer Research United (ACCRU). ACCRU is a cancer research network conducting clinical trials that translate the latest discoveries into new therapies for cancer treatment and symptom management.
ACCRU leadership is now collaborating with Quorum to provide a central institutional review board (IRB) option for network members participating in ACCRU clinical trials.
“We are excited to offer our members the opportunity to use Quorum as a central IRB for certain ACCRU studies, with the goal of streamlining the study activation process. This collaboration is part of our ongoing efforts to improve clinical trial administration processes so that our members can activate and enroll patients on ACCRU trials more rapidly,” said Tanios Bekaii-Saab, M.D., interim chair, ACCRU.
“Quorum is proud to collaborate with ACCRU and apply our oncology expertise to help lead research to cures,” said Cami Gearhart, CEO, Quorum. “We applaud the mission of ACCRU and are pleased that our streamlined study activation process is recognized by a prestigious network dedicated to high-quality cancer clinical research. Quorum continuously strives for agile and innovative independent ethics review services.”
The ACCRU network includes more than 110 leading academic medical centers and community oncology practices in the United States and internationally. ACCRU conducts industry-sponsored and investigator-initiated, phase II and III cancer treatment and symptom management trials across many types of cancer.
Quorum Review IRB is the most preferred central IRB. Clients achieve reduced fulfillment time and gain the largest offering of complimentary study support services. We are the only IRB to offer harmonized IRB and IBC review, API integrations, and consulting services that move your research forward.
Director of Marketing
Quorum Review IRB